ADCendo

Copenhagen, Denmark

Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.

$135.0M raised

Apr 2026

Series C

Top Investors

TPGRA Capital ManagementBpifranceNovo HoldingsTCG Crossover

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ADCendo raised?

ADCendo has raised $135.0M in total funding. The most recent round was Series C. The last funding was announced in April 2026.

Who are ADCendo's investors?

ADCendo's investors include TPG, RA Capital Management, Bpifrance, Novo Holdings, TCG Crossover.

Where is ADCendo headquartered?

ADCendo is headquartered in Copenhagen, Denmark.

What does ADCendo do?

Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.

What stage is ADCendo at?

ADCendo is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 14, 2026.

MLA

"ADCendo — Funding & Investors." VCBacked, April 14, 2026, https://www.vcbacked.co/company/adcendo. Accessed June 3, 2026.

APA

VCBacked. (2026). ADCendo — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/adcendo

Wikipedia (cite web)

{{cite web |title=ADCendo — Funding & Investors |url=https://www.vcbacked.co/company/adcendo |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 14, 2026.